AlEissa Mariam M, Alhawsawi Abrar A, Alonazi Raghad, Magharbil Enas, Aljahdali Abeer, AlBalawi Hani B, Alali Naif M, Hameed Syed, Abu-Amero Khaled K, Magliyah Moustafa S
Research Department, King Khaled Eye Specialist Hospital, Riyadh 11462, Saudi Arabia.
College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Genes (Basel). 2025 Jul 21;16(7):847. doi: 10.3390/genes16070847.
Gene therapy has emerged as a promising treatment for several eye diseases since it may restore vision and stop blindness. Many eye diseases, including retinitis pigmentosa and macular degeneration, have historically been rather difficult to treat and usually cause permanent vision loss. However, thanks to advances in gene therapy, many disorders can now be effectively targeted and genetically changed, providing a safer, more direct, maybe even curative approach. By introducing, altering, or repairing specific genes inside the eye, gene therapy seeks to fix the defective genes causing these disorders, thereby improving general eye health and visual ability. Voretigene neparvovec is one FDA- and EMA-approved treatment for mutations. Retinitis pigmentosa, age-related macular degeneration, X-linked retinoschisis, choroideremia, and Stargardt disease are among the several eye disorders still under clinical trials, and experimental treatment is in progress. As research on gene therapy develops, it opens the path for groundbreaking treatments that could fundamentally change the ophthalmic care scene.
基因疗法已成为治疗多种眼部疾病的一种有前景的治疗方法,因为它可能恢复视力并阻止失明。包括色素性视网膜炎和黄斑变性在内的许多眼部疾病,历来都相当难以治疗,通常会导致永久性视力丧失。然而,由于基因疗法的进展,现在许多疾病都可以有效地靶向并进行基因改变,提供了一种更安全、更直接、甚至可能治愈的方法。通过在眼内引入、改变或修复特定基因,基因疗法旨在修复导致这些疾病的缺陷基因,从而改善整体眼部健康和视觉能力。维莫瑞生是一种经美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)批准用于治疗特定突变的药物。色素性视网膜炎、年龄相关性黄斑变性、X连锁视网膜劈裂症、脉络膜骨瘤和斯塔加特病等几种眼部疾病仍在临床试验中,实验性治疗正在进行。随着基因疗法研究的发展,它为可能从根本上改变眼科护理局面的突破性治疗开辟了道路。